Testing GKT for memory problems in type 2 diabetes
Part of Brain & nervous system, Mental health clinical trials.
This trial studies whether the medicine GKT can improve or slow memory decline in people age 65+ who have type 2 diabetes and mild cognitive impairment. You may be considered if you can complete thinking/memory tests and take tablets, and you meet several health and medication requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes (not type 1) and are age 65 or older
- You have mild cognitive impairment and can complete memory/thinking tests
- You can safely swallow pills
- You have not had a stroke or blood clot in the brain in the past
- You have not had certain recent brain or heart events (within the last 3 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at ways to catch early thinking and memory changes in people with type 2 diabetes. By joining, you may help doctors learn how to spot problems sooner and find better ways to help.
This trial tests whether a combination of cilostazol (a blood flow medication) and ginkgo (a herbal supplement) can help protect memory and thinking skills in people over 60 with type 2 diabetes. You may join if your memory is slightly below normal but not severely impaired.
This trial tests whether adding ginkgo biloba extract tablets to standard stroke care helps improve memory and thinking in people who had a mild stroke. You may join if you are 55 or older, had a mild stroke in the last 1 to 2 weeks, and now have some cognitive difficulties.
This trial tests whether a natural extract from ginkgo biloba can help people with mild memory or thinking problems caused by small vessel disease in the brain. It looks for adults aged 50 to 75 who have had these symptoms for at least 3 months but can still live independently.
This trial tests whether a specific ginkgo biloba extract (EGb761) can improve thinking and memory in people with mild cognitive impairment (MCI). It also looks at changes in blood markers related to the condition.
This study tests whether Ginkgo biloba extract can improve blood markers and cognitive function in people with mild cognitive impairment (early memory loss). Researchers will measure changes in blood biomarkers to understand how Ginkgo may help protect brain health.
Hear when a new Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.